Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination of epac direct or indirect agonists with oncolytic viruses

A technology of oncolytic virus and agonist, which is applied in the field of joint application of Epac direct or indirect agonist and oncolytic virus, which can solve the problems of slow clearance, restriction of virus replication, narrow anti-tumor spectrum of oncolytic virus, etc.

Active Publication Date: 2018-10-12
GUANGZHOU VIROTECH PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

First, the anti-tumor spectrum of oncolytic viruses is relatively narrow: tumor cells sensitive to oncolytic viruses are accompanied by more viral replication; tumor cells insensitive to oncolytic viruses are accompanied by less viral replication
Second, in vivo, viral replication is restricted over time and slowly cleared by the body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of epac direct or indirect agonists with oncolytic viruses
  • Combination of epac direct or indirect agonists with oncolytic viruses
  • Combination of epac direct or indirect agonists with oncolytic viruses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1 Epac agonists significantly increase the replication of oncolytic viruses.

[0094] 1) Epac agonists significantly increase the expression of oncolytic virus proteins.

[0095] Material:

[0096] Human colorectal cell carcinoma HCT116, human pancreatic cell carcinoma Capan-1, human immortalized normal liver cell line L-02, M1 virus, high-glucose DMEM medium, db-cAMP (Sigma, USA).

[0097] Western bolt: cell total protein extract ( Mammalian Protein Extraction Reagent, Thermo), E1 antibody (homemade), NS3 antibody (homemade), GAPDH antibody (Bioworld USA);

[0098] method:

[0099] a) Cell culture: human colorectal cancer cell line HCT116, human pancreatic cancer cell line Capan-1, human immortalized normal liver cell line L-02, grown in a medium containing 10% FBS, 100 U / ml penicillin and 0.1 mg / ml streptomycin in DMEM complete medium or primary cell culture medium; all cell lines were placed in 5% CO 2 , cultured and subcultured in a closed incubator wi...

Embodiment 2

[0144] Example 2 Epac agonist and M1 virus selectively cause tumor cell death

[0145] 1) Epac agonist and M1 virus selectively cause tumor cell lesions

[0146] Material:

[0147] Human colorectal cancer HCT116, human immortalized normal liver cell line L-02, M1 virus, high-glucose DMEM medium, inverted phase-contrast microscope.

[0148] method:

[0149] a) Cell culture: human colorectal cancer HCT116, human immortalized normal liver cell line L-02, grown in DMEM complete medium containing 10% FBS, 100 U / ml penicillin and 0.1 mg / ml streptomycin; All cell lines were placed in 5% CO 2 , cultured and subcultured in a closed incubator with a constant temperature of 37°C (95% relative humidity), and observed the growth with an inverted microscope. The cells were subcultured every 2-3 days, and the cells in the logarithmic growth phase were taken for formal experiments.

[0150] b) Observation under the cell microscope: cells in the logarithmic growth phase were selected, and...

Embodiment 3

[0163] Example 3 Epac agonists enhance the oncolytic effect of M1 through Epac1, not PKA

[0164] 1) Interference with PKA cannot cancel the enhanced oncolytic effect of cAMP activation

[0165] Material:

[0166] Human colorectal cancer HCT116, M1 virus, high glucose DMEM medium, MTT, siRNA, RNAiMAX, inverted phase contrast microscope.

[0167] method:

[0168] a) Cell culture: human colorectal cancer HCT116, grown in DMEM complete medium containing 10% FBS, 100U / ml penicillin and 0.1mg / ml streptomycin; cells placed in 5% CO 2 , cultured and subcultured in a closed incubator with a constant temperature of 37°C (95% relative humidity), and observed the growth with an inverted microscope. The cells were subcultured every 2-3 days, and the cells in the logarithmic growth phase were taken for formal experiments.

[0169] b) RNA interference: select logarithmic growth phase cells, DMEM complete culture medium (containing 10% fetal bovine serum, 1% double antibody) to make cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are a pharmaceutical composition containing a direct or indirect agonist of Epac and an oncolytic virus, medication set, and the use thereof in the preparation of medication for treating tumors, in particular, tumors insensitive to the oncolytic virus. Also disclosed is a method of producing an oncolytic virus in-vitro.

Description

technical field [0001] The present invention relates to the combined application of Epac direct or indirect agonist and oncolytic virus in the treatment of tumors, specifically, a pharmaceutical composition comprising Epac direct or indirect agonist and oncolytic virus, comprising independently packaged Epac Medicine set of direct or indirect agonist and independently packaged oncolytic virus, method for producing oncolytic virus in vitro, and combination of Epac direct or indirect agonist and oncolytic virus in treating tumors, especially for said oncolytic virus Use in sensitive tumors. Background technique [0002] Tumors arise from the accumulation of genetic and epigenetic changes in normal cells that drive the transformation of normal cells into malignancy. This complex pathological change process determines the diversity of mechanisms in the occurrence, maintenance and metastasis of different tumors. At present, surgical resection, chemotherapy and radiotherapy are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P35/00A61K35/76
CPCA61K35/76A61K45/00Y02A50/30
Inventor 颜光美李凯肖晓胡骏梁剑开林园张海鹏邱鹏新朱文博银巍林穗珍
Owner GUANGZHOU VIROTECH PHARMA